

Isabel Boivin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2977355/publications.pdf>

Version: 2024-02-01

9
papers

621
citations

1162367

8
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

1547
citing authors

#	ARTICLE	IF	CITATIONS
1	Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2019, 36, 84-99.e8.	7.7	163
2	GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. <i>Blood</i> , 2016, 127, 2018-2027.	0.6	148
3	Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. <i>Blood</i> , 2016, 127, 3054-3061.	0.6	70
4	H3 K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations. <i>Blood</i> , 2017, 130, 2204-2214.	0.6	62
5	RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. <i>Blood</i> , 2016, 127, 2498-2501.	0.6	60
6	Genetic characterization of ABT-199 sensitivity in human AML. <i>Leukemia</i> , 2020, 34, 63-74.	3.3	58
7	<i>HLF</i> expression defines the human hematopoietic stem cell state. <i>Blood</i> , 2021, 138, 2642-2654.	0.6	31
8	Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. <i>Blood Advances</i> , 2019, 3, 552-563.	2.5	24
9	HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition. <i>Blood Advances</i> , 2022, 6, 4793-4806.	2.5	5